Exo Therapeutics Inc. has presented data on its preclinical program targeting TBK1/STING interaction of the cGAS-STING pathway. The company has identified potent, selective exosite-targeted TBK1/STING inhibitors, optimized properties toward development candidate nomination and demonstrated efficacy across preclinical models.